| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |